Download FREE Sample
Report Overview
Oncology companion diagnostics are specialized tests that help determine the most effective cancer treatment for individual patients by identifying specific biomarkers. These diagnostics ensure that targeted therapies are administered to patients who are most likely to benefit, improving treatment efficacy and minimizing adverse effects. They play a crucial role in personalized medicine by guiding oncologists in selecting therapies based on a patient's genetic profile. The development of these tests is often linked with targeted cancer drugs, making them essential in modern oncology care.
To learn more about this report, download the PDF brochure
Expanding role of companion diagnostics in targeted cancer therapies
The increasing reliance on targeted therapies in oncology has significantly driven the demand for companion diagnostics (CDx). These diagnostics help identify specific cancer mutations, enabling precise treatment selection and minimizing side effects. Regulatory agencies like the FDA advocate for broader CDx applications, allowing single tests to guide multiple drug options for the same mutation, improving clinical efficiency. Despite these advancements, gaps in genomic testing remain-highlighted by a 2020 study showing that nearly a quarter of advanced NSCLC (Non-Small Cell Lung Cancer) patients in the US did not receive recommended biomarker testing before treatment. Given that most NSCLC patients could benefit from targeted therapy, improving CDx accessibility and adoption remains critical. As awareness of personalized medicine grows aatory support strengthens, oncology companion diagnostics continue to play an essential role in optimizing cancer treatment outcomes.
Technological innovations enhancing companion diagnostics market growth
Advancements in liquid biopsy and next-generation sequencing (NGS) are transforming oncology diagnostics by enabling non-invasive, comprehensive genetic testing. Liquid biopsy allows for ctDNA analysis from blood samples, improving early cancer detection and treatment monitoring. Meanwhile, NGS facilitates multi-gene profiling in a single test, enhancing precision in therapy selection. However, the rapid development of targeted therapies has created challenges in aligning CDx availability with new drug launches. To address this, regulatory agencies require clinical validation of at least one diagnostic test per drug class, ensuring consistent biomarker detection. AI-driven analytics further refine diagnostic accuracy and efficiency, accelerating the integration of personalized medicine. As these technologies advance, they are expected to enhance accessibility, improve patient outcomes, and drive the continued expansion of the oncology companion diagnostics market.
To learn more about this report, download the PDF brochure
Competitive Landscape Analysis
The global oncology companion diagnostic market is marked by the presence of established and emerging market players such as Agilent Technologies Inc.; Illumina Inc.; QIAGEN; Thermo Fisher Scientific Inc.; Foundation Medicine Inc.; Myriad Genetics, Inc.; F. Hoffmann-La Roche Ltd.; BioMrieux; Abbott; Leica Biosystems; Guardant Health, Inc.; and EntroGen, Inc. among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Report Scope
| Report Metric | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 - 2024 |
| Forecast Period | 2025 - 2030 |
| 10% | |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Product & Services, Technology, Cancer Type, and End-User |
| Regional Scope |
|
| Key Companies Mapped | Agilent Technologies Inc.; Illumina Inc.; QIAGEN; Thermo Fisher Scientific Inc.; Foundation Medicine Inc.; Myriad Genetics, Inc.; F. Hoffmann-La Roche Ltd.; BioMrieux; Abbott; Leica Biosystems; Guardant Health, Inc.; and EntroGen, Inc. among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Oncology Companion Diagnostic Market Segmentation
This report by Medi-Tech Insights provides thesize of the global oncology companion diagnostic market at theregional- and country-level from 2023 to 2030. The report further segments the market based on product & services, technology, cancer type, and end-user.
Market Size & Forecast (2023-2030), By Product & Services, USD Million
- Product
- Instrument
- Consumables
- Software
- Services
Market Size & Forecast (2023-2030), By Technology, USD Million
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Immunohistochemistry (IHC)
- In Situ Hybridization (ISH)
- Others
Market Size & Fo30), By Cancer Type, USD Million
- Lung Cancer
- Breast Cancer
- Leukaemia
- Colorectal Cancer
- Prostate Cancer
- Others
Market Size & Forecast (2023-2030), By End-user, USD Million
- Hospitals
- Diagnostic Laboratory
- Academic & Research Institutes
- Others
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the oncology companion diagnostic market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the oncology companion diagnostic market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
Need a More Tailored Analysis?
- Discuss the market sizing methodology and forecast assumptions with our healthcare analysts.
- Expand the scope with additional countries, market segments, technologies, or competitor profiling.
- Use the insights to support strategic planning, market entry, commercial due diligence, and long-term revenue growth initiatives.
